A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20
Purpose
This study aims to learn how the body handles tilrekimig when given with another medicine called recombinant human hyaluronidase PH20 (rHuPH20). rHuPH20 is approved to help some medicines be taken up by the body when they are given together as an injection (shot) under the skin.
Condition
- Healthy
Eligibility
- Eligible Ages
- Between 18 Years and 65 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- BMI of 16-32 kg/m2; and a total body weight >50 kg (110 lb). - Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. Participants should be able to understand and sign informed consent
Exclusion Criteria
- Evidence or history of clinically significant any medical condition - History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBcAb or HCVAb. - Evidence of active, latent, or inadequately treated infection with Mycobacterium TB - History of allergic or anaphylactic reaction with any biologic agents.
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Basic Science
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental tilrekimig and rHuPH20 |
a single dose of co-mixed tilrekimig and rHuPH20 |
|
Recruiting Locations
New Haven Pfizer Clinical Research Unit (NH PCRU)
New Haven, Connecticut 06511
New Haven, Connecticut 06511
More Details
- Status
- Recruiting
- Sponsor
- Pfizer